Get a Quote

LEMBOREXANT
CAS NO.: 1369764-02-2
Chemical Formula: C22H20F2N4O2
Molecular Weight: 410.4000
DMF&GMP status: Please contact us for more details.
Description:
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switch-off" wake-promoting circuits. Whereas historically popular pharmacologic treatments for insomnia (e.g. [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. [suvorexant]) act to counteract inappropriate wakefulness. This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from insomnia.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
LEMBOREXANTTABLET;ORAL5MGDAYVIGOEISAI INC
LEMBOREXANTTABLET;ORAL10MGDAYVIGOEISAI INC
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
826884809/20/2031DSDPU-2791
1018865210/21/2035DPU-2791
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 04/07/2025